Collectionner le produit
Détails du produit
Application
- Immunization
- Cell based assay (FACS or functional assay)
- Screening (ELISA)
Synonyms
MS4A1, CD20, MS4A-1
Source
Human CD20 Full Length Protein-VLP (CDP-H52P6) is expressed from human 293 cells (HEK293). It contains AA Met 1 - Pro 297 (Accession # P11836-1).
Predicted N-terminus: Met
Molecular Characterization
*The isotype control of empty/mock VLP (Cat. No. VLP-N5213) is sold separately and not included in protein, you can follow the link for product information.
Structure
Virus-like particles (VLPs) are protein particles that mimic the shape of viruses but lack a viral genome, and incorporating transmembrane proteins on the external surface.
Synthesis Process
Envelope virus-like particles (eVLPs) are produced by co-expressing target membrane proteins with viral structural proteins in mammalian cells, enabling native embedding of membrane proteins into the lipid bilayer during VLP budding. This approach preserves authentic conformation, post-translational modifications, and orientation, while creating a completely detergent-free environment with repetitive multivalent display and strong immunogenicity making them ideal for immunization, binding assays in antibody discovery and screening (ELISA), and cell-based assays such as FACS, etc.
Endotoxin
Less than 1.0 EU per μg by the LAL method / rFC method.
Purity
>95% as determined by SEC-HPLC.
Formulation
The VLPs are highly immunogenic, so the immunization strategy should be optimized (antigen dose, regimen and adjuvant).
Supplied as 0.2 μm filtered solution in PBS, pH7.4 with trehalose as protectant.
Contact us for customized product form or formulation.
Shipping and Storage
This product is supplied and shipped on dry ice.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
- The product MUST be stored at -70°C or lower upon receipt;
- -70°C for 12 months under sterile conditions.
ACRO Quality Management System
Les clients ont également consulté
Affichage des données
SEC-HPLC
The purity of Human CD20 Full Length Protein-VLP (Cat. No. CDP-H52P6) was greater than 95% as determined by SEC-HPLC.
Bioactivity-ELISA
Immobilized Human CD20 Full Length Protein-VLP (Cat. No. CDP-H52P6) at 5 μg/mL (100 μL/well) can bind Rituximab biosimilar (Cat. No. CD0-M36) with a linear range of 0.2-3 μg/mL (QC tested).
Protocol
Immobilized Human CD20 Full Length Protein-VLP (Cat. No. CDP-H52P6) at 5 μg/mL (100 μL/well) can bind Ofatumumab with a linear range of 0.2-3 μg/mL (QC tested).
Protocol
Immobilized Human CD20 Full Length Protein-VLP (Cat. No. CDP-H52P6) at 5 μg/mL (100 μL/well) can bind Obinutuzumab with a linear range of 0.2-1 ng/mL (Routinely tested).
Protocol
Identity-DLS
The mean peak Radius of VLP is 60-80 nm with more than 95% intensity as determined by dynamic light scattering (DLS).
Avis des utilisateurs Publier un commentaire
B***n2026-06-19
J'aimeI purchased this alongside the matched control antigen and they worked together very well. Delivery was very fast, all the necessary information was included with the vials, and the binding assay I needed worked well with the matched control. I was pleased with my choice of Acro Bio.
Introduction de fond
Progrès de frontière
Progrès du développement médicamenteux- Nom anglais：
B-lymphocyte antigen CD20
- Catégorie：
- Nombre de médicaments répertoriés：
35 Détails
- Nombre de médicaments cliniques：
132 Détails
- Étape de développement la plus élevée：
Approved
Contact Us
Drug Candidate Licensing
